(HRTX) Heron Therapeuti - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 156m USD | Total Return: -63.6% in 12m

Stock Pain Relief, Chemotherapy Support, Drug Delivery
Total Rating 15
Risk 31
Buy Signal -0.56
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 156m
Avg Trading Vol: 1.48M USD
ATR: 10.00%
Peers RS (IBD): 1.0
Risk 5d forecast
Volatility75.2%
Rel. Tail Risk-17.8%
Reward TTM
Sharpe Ratio-1.28
Alpha-83.38
Character TTM
Beta1.028
Beta Downside2.672
Drawdowns 3y
Max DD81.25%
CAGR/Max DD-0.31
EPS (Earnings per Share) EPS (Earnings per Share) of HRTX over the last years for every Quarter: "2021-03": -0.58, "2021-06": -0.62, "2021-09": -0.51, "2021-12": -0.54, "2022-03": -0.63, "2022-06": -0.55, "2022-09": -0.38, "2022-12": -0.17, "2023-03": -0.27, "2023-06": -0.35, "2023-09": -0.17, "2023-12": -0.07, "2024-03": -0.02, "2024-06": -0.06, "2024-09": -0.0317, "2024-12": 0.02, "2025-03": 0.0134, "2025-06": -0.02, "2025-09": -0.1, "2025-12": -0.02,
EPS CAGR: 213.70%
EPS Trend: 84.8%
Last SUE: -0.09
Qual. Beats: 0
Revenue Revenue of HRTX over the last years for every Quarter: 2021-03: 20.018, 2021-06: 22.443, 2021-09: 23.23, 2021-12: 20.655, 2022-03: 23.457, 2022-06: 27.63, 2022-09: 26.557, 2022-12: 30.028, 2023-03: 29.615, 2023-06: 31.762, 2023-09: 31.434, 2023-12: 34.233, 2024-03: 34.67, 2024-06: 36.024, 2024-09: 32.81, 2024-12: 40.781, 2025-03: 38.903, 2025-06: 37.2, 2025-09: 38.213, 2025-12: 40.588,
Rev. CAGR: 15.74%
Rev. Trend: 93.2%
Last SUE: 0.41
Qual. Beats: 0
Risks
Technicals: choppy
Description: HRTX Heron Therapeuti March 05, 2026

Heron Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapeutic products. Biotechnology companies often rely on extensive research and development pipelines to bring new drugs to market.

The company utilizes its proprietary Biochronomer drug delivery technology, which provides extended release of pharmacological agents from days to weeks with a single administration. This technology addresses a key challenge in drug delivery: maintaining therapeutic levels over time without frequent dosing.

Herons product portfolio includes SUSTOL and CINVANTI, both aimed at preventing chemotherapy-induced nausea and vomiting. Chemotherapy-induced nausea and vomiting remain significant side effects that can impact patient quality of life and treatment adherence.

The company is also developing ZYNRELEF, a dual-acting local anesthetic, and APONVIE, for the prevention of postoperative nausea and vomiting. Local anesthetics and antiemetics are crucial in pain management and surgical recovery.

To further understand HRTXs market position and financial health, consider exploring its detailed financials on ValueRay.

Headlines to Watch Out For
  • ZYNRELEF sales growth drives revenue expansion
  • CINVANTI and SUSTOL sales contribute to stable revenue
  • Regulatory approval of new drug candidates impacts future growth
  • Competition in pain management and antiemetic markets affects market share
  • Research and development expenses influence profitability
Piotroski VR‑10 (Strict, 0-10) 2.0
Net Income: -20.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.11 > 0.02 and ΔFCF/TA -0.51 > 1.0
NWC/Revenue: 91.65% < 20% (prev 81.48%; Δ 10.17% < -1%)
CFO/TA -0.11 > 3% & CFO -27.6m > Net Income -20.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.48 > 1.5 & < 3
Outstanding Shares: last quarter (166.7m) vs 12m ago 8.85% < -2%
Gross Margin: 73.31% > 18% (prev 0.73%; Δ 7.26k% > 0.5%)
Asset Turnover: 63.35% > 50% (prev 61.89%; Δ 1.47% > 0%)
Interest Coverage Ratio: -3.07 > 6 (EBITDA TTM -12.1m / Interest Expense TTM 4.90m)
Altman Z'' -15.00
A: 0.55 (Total Current Assets 238.1m - Total Current Liabilities 96.1m) / Total Assets 255.9m
B: -7.58 (Retained Earnings -1.94b / Total Assets 255.9m)
C: -0.06 (EBIT TTM -15.0m / Avg Total Assets 244.5m)
D: -8.02 (Book Value of Equity -1.94b / Total Liabilities 241.5m)
Altman-Z'' Score: -29.91 = D
Beneish M -3.04
DSRI: 1.06 (Receivables 89.6m/78.9m, Revenue 154.9m/144.3m)
GMI: 1.00 (GM 73.31% / 73.21%)
AQI: 0.76 (AQ_t 0.02 / AQ_t-1 0.03)
SGI: 1.07 (Revenue 154.9m / 144.3m)
TATA: 0.03 (NI -20.2m - CFO -27.6m) / TA 255.9m)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of HRTX shares? As of April 01, 2026, the stock is trading at USD 0.80 with a total of 1,238,050 shares traded.
Over the past week, the price has changed by +4.66%, over one month by -33.32%, over three months by -38.45% and over the past year by -63.63%.
Is HRTX a buy, sell or hold? Heron Therapeuti has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy HRTX.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the HRTX price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 4.3 441.3%
Analysts Target Price 4.3 441.3%
HRTX Fundamental Data Overview March 28, 2026
P/E Forward = 46.9484
P/S = 1.0042
P/B = 11.0513
P/EG = -0.18
Revenue TTM = 154.9m USD
EBIT TTM = -15.0m USD
EBITDA TTM = -12.1m USD
Long Term Debt = 140.6m USD (from longTermDebt, last quarter)
Short Term Debt = 780k USD (from shortTermDebt, two quarters ago)
Debt = 140.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 112.0m USD (from netDebt column, last quarter)
Enterprise Value = 249.6m USD (155.6m + Debt 140.6m - CCE 46.6m)
Interest Coverage Ratio = -3.07 (Ebit TTM -15.0m / Interest Expense TTM 4.90m)
EV/FCF = -8.94x (Enterprise Value 249.6m / FCF TTM -27.9m)
FCF Yield = -11.18% (FCF TTM -27.9m / Enterprise Value 249.6m)
FCF Margin = -18.02% (FCF TTM -27.9m / Revenue TTM 154.9m)
Net Margin = -13.04% (Net Income TTM -20.2m / Revenue TTM 154.9m)
Gross Margin = 73.31% ((Revenue TTM 154.9m - Cost of Revenue TTM 41.3m) / Revenue TTM)
Gross Margin QoQ = 81.15% (prev 59.74%)
Tobins Q-Ratio = 0.98 (Enterprise Value 249.6m / Total Assets 255.9m)
Interest Expense / Debt = 0.71% (Interest Expense 1.00m / Debt 140.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -11.9m (EBIT -15.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.48 (Total Current Assets 238.1m / Total Current Liabilities 96.1m)
Debt / Equity = 9.81 (Debt 140.6m / totalStockholderEquity, last quarter 14.3m)
 Debt / EBITDA = -9.26 (negative EBITDA) (Net Debt 112.0m / EBITDA -12.1m)
 Debt / FCF = -4.01 (negative FCF - burning cash) (Net Debt 112.0m / FCF TTM -27.9m)
 Total Stockholder Equity = -6.62m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.26% (Net Income -20.2m / Total Assets 255.9m)
 RoE = 304.9% (negative equity) (Net Income TTM -20.2m / Total Stockholder Equity -6.62m)
 RoCE = -11.22% (EBIT -15.0m / Capital Employed (Equity -6.62m + L.T.Debt 140.6m))
 RoIC = -7.98% (negative operating profit) (NOPAT -11.9m / Invested Capital 148.8m)
 WACC = 5.31% (E(155.6m)/V(296.2m) * Re(9.60%) + D(140.6m)/V(296.2m) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.32%
 [DCF] Fair Price = unknown (Cash Flow -27.9m)
 EPS Correlation: 84.78 | EPS CAGR: 213.7% | SUE: -0.09 | # QB: 0
Revenue Correlation: 93.16 | Revenue CAGR: 15.74% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=-0.03 | Chg7d=+0.020 | Chg30d=+0.020 | Revisions Net=+1 | Growth EPS=+43.5% | Growth Revenue=+13.0%
EPS next Year (2027-12-31): EPS=0.51 | Chg7d=+0.055 | Chg30d=+0.055 | Revisions Net=+1 | Growth EPS=+1800.0% | Growth Revenue=+20.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
Additional Sources for HRTX Stock Fund Manager Positions: Dataroma · Stockcircle